104 related articles for article (PubMed ID: 2680924)
1. Molecular mechanisms involved in human autoimmune diseases: relevance of chronic antigen presentation. Class II expression and cytokine production.
Feldmann M
Immunol Suppl; 1989; 2():66-71; discussion 72-3. PubMed ID: 2680924
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of the antigen presenting cell in rat autoimmune myocarditis: evidence of bone marrow derivation and non-requirement for MHC class I compatibility with pathogenic T cells.
Ratcliffe NR; Wegmann KW; Zhao RW; Hickey WF
J Autoimmun; 2000 Nov; 15(3):369-79. PubMed ID: 11040077
[TBL] [Abstract][Full Text] [Related]
3. Class II major histocompatibility complex and organ specific autoimmunity in man.
Foulis AK
J Pathol; 1986 Sep; 150(1):5-11. PubMed ID: 2946837
[TBL] [Abstract][Full Text] [Related]
4. The selective antigen-presenting cell capacity of activated B lymphocytes in HLA-II-restricted responses of CD4+ T lymphocytes.
Van Der Pouw Kraan TT; Stiekema FE; Teunissen MB; Bos JD; Kapsenberg L
Immunology; 1989 Oct; 68(2):147-53. PubMed ID: 2572541
[TBL] [Abstract][Full Text] [Related]
5. HLA class II antigens: structure, function, and expression in immunodeficiencies, autoimmune diseases, and allograft rejection.
Touraine JL; Bétuel H; Pouteil-Noble C; Royo C
Adv Nephrol Necker Hosp; 1989; 18():325-34. PubMed ID: 2493721
[TBL] [Abstract][Full Text] [Related]
6. [Immunopathology of chronic liver diseases].
Meyer zum Büschenfelde KH
Verh Dtsch Ges Pathol; 1995; 79():186-97. PubMed ID: 8600684
[TBL] [Abstract][Full Text] [Related]
7. HLA class II transgenic mice mimic human inflammatory diseases.
Mangalam AK; Rajagopalan G; Taneja V; David CS
Adv Immunol; 2008; 97():65-147. PubMed ID: 18501769
[TBL] [Abstract][Full Text] [Related]
8. Antigen presentation by cells that are not of bone marrow origin.
Geppert TD; Lipsky PE
Reg Immunol; 1989; 2(1):60-71. PubMed ID: 2518360
[TBL] [Abstract][Full Text] [Related]
9. Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor, IFN-gamma, and IL-3.
Gosselin EJ; Wardwell K; Rigby WF; Guyre PM
J Immunol; 1993 Aug; 151(3):1482-90. PubMed ID: 8335942
[TBL] [Abstract][Full Text] [Related]
10. HLA class II polymorphism: implications for genetic susceptibility to autoimmune disease.
Gregersen PK
Lab Invest; 1989 Jul; 61(1):5-19. PubMed ID: 2664347
[TBL] [Abstract][Full Text] [Related]
11. Exploring the reciprocal relationship between immunity and inflammation in chronic inflammatory arthritis.
Cope AP
Rheumatology (Oxford); 2003 Jun; 42(6):716-31. PubMed ID: 12730506
[TBL] [Abstract][Full Text] [Related]
12. Infections and autoimmune diseases.
Bach JF
J Autoimmun; 2005; 25 Suppl():74-80. PubMed ID: 16278064
[TBL] [Abstract][Full Text] [Related]
13. Thyroid-associated eye disease.
Heufelder AE; Joba W
Strabismus; 2000 Jun; 8(2):101-11. PubMed ID: 10980691
[TBL] [Abstract][Full Text] [Related]
14. Antigen presentation by interferon-gamma-treated thyroid follicular cells inhibits interleukin-2 (IL-2) and supports IL-4 production by B7-dependent human T cells.
Lombardi G; Arnold K; Uren J; Marelli-Berg F; Hargreaves R; Imami N; Weetman A; Lechler R
Eur J Immunol; 1997 Jan; 27(1):62-71. PubMed ID: 9021999
[TBL] [Abstract][Full Text] [Related]
15. Control of MHC class II gene expression in autoimmune, infectious, and neoplastic diseases.
Guardiola J; Maffei A
Crit Rev Immunol; 1993; 13(3-4):247-68. PubMed ID: 8110378
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?
Altomonte M; Fonsatti E; Visintin A; Maio M
Oncogene; 2003 Sep; 22(42):6564-9. PubMed ID: 14528281
[TBL] [Abstract][Full Text] [Related]
17. Localization and characterization of major histocompatibility complex class II-positive cells in the posterior segment of the eye: implications for induction of autoimmune uveoretinitis.
Forrester JV; McMenamin PG; Holthouse I; Lumsden L; Liversidge J
Invest Ophthalmol Vis Sci; 1994 Jan; 35(1):64-77. PubMed ID: 8300365
[TBL] [Abstract][Full Text] [Related]
18. Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor.
Mueller RB; Skapenko A; Grunke M; Wendler J; Stuhlmuller B; Kalden JR; Schulze-Koops H
Arthritis Rheum; 2005 Feb; 52(2):451-60. PubMed ID: 15692975
[TBL] [Abstract][Full Text] [Related]
19. Immunoregulation of autoimmune diseases.
van Eden W
Hum Immunol; 2006 Jun; 67(6):446-53. PubMed ID: 16728268
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of T cell activation by blockade of MHC class II molecules.
Adorini L; Valli A; Guéry JC
Semin Immunol; 1991 Jul; 3(4):231-6. PubMed ID: 1932705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
